Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448935 | 1.00 | CTSL (0.44) | CTSLCTSKCTSBALDH1A1HDAC8 | |
| SCHEMBL3047503 | 1.00 | CTSL (0.44) | CTSLCTSKCTSBALDH1A1HDAC8 | |
| SCHEMBL4448932 | 1.00 | CTSL (0.44) | CTSLCTSKCTSBALDH1A1HDAC8 | |
| SCHEMBL6741915 | 0.89 | ATM (0.48) | CTSLCTSKCTSBHDAC8ELANE | |
| SCHEMBL25348299 | 0.89 | ATM (0.48) | CTSLCTSKCTSBHDAC8ELANE | |
| SCHEMBL19318679 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MMP2ANPEPPEPDMEN1 | |
| SCHEMBL12098413 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MMP2ANPEPPEPDMEN1 | |
| SCHEMBL12098416 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MMP2ANPEPPEPDMEN1 | |
| SCHEMBL1440998 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MMP2ANPEPPEPDMEN1 | |
| SCHEMBL24441116 | 0.87 | CTSL (0.43) | CTSLCTSKCTSBHDAC8ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2066688-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CTSL 2124/4885CTSK 1630/4885CTSB 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.